Treatment for patients with Ovarian, Fallopian Tube or Primary Peritoneal Cancer

What we are studying

The purpose of this study is to find out if the drugs elesclomol sodium and paclitaxel will work in treating your type of cancer and to find out what side effects are caused by treatment with this drug combination. Paclitaxel is a drug which has shown effectiveness in treating ovarian, uterine and cervical cancer. Elesclomol sodium is an investigational drug that is thought to help make cancer cells more responsive to paclitaxel. In a small comparative trial in advanced melanoma (skin cancer), the combination of paclitaxel and elesclomol was more effective than paclitaxel alone in shrinking cancerous tumors and slowing cancer growth and progression. However, in a conflicting larger study in advanced melanoma, there were more deaths in the paclitaxel-elesclomol arm than the paclitaxel alone arm (80 vs. 53).

Who we are studying

  • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Diagnosis of ovarian
  • Fallopian tube or primary peritoneal cancer
  • Have not had prior treatment with elesclomol sodium

What is involved

  • 1 Screening visit
  • Treatment with Paclitaxel and elesclomol sodium once a week for 3 weeks until disease progression
  • Follow-Up after treatment will occur approximately every 3 months for the first 2 years and then every 6 months for 3 years

Contact Information

Study Coordinator
Melissa Swain
Email
mswain@wakehealth.edu
Phone
336-716-9428

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.